Novel models for predicting individualized outcomes in patients with advanced hepatocellular carcinoma receiving immunotherapy - Scorecard - MDSpire

Novel models for predicting individualized outcomes in patients with advanced hepatocellular carcinoma receiving immunotherapy

  • By

  • Chao Chen

  • Yang Wang

  • Yan Zhao

  • Wenyan Cao

  • Ao Chen

  • Xiufeng Liu

  • Zhan Shi

  • Jie Shen

  • June 1, 2026

  • 0 min

Share

Clinical Scorecard: Innovative Predictive Models for Tailoring Outcomes in Advanced Hepatocellular Carcinoma Patients Undergoing Immunotherapy

At a Glance

CategoryDetail
Condition
Key MechanismsImmunotherapy using anti-PD-1 drugs (context needed)
Target Population
Care Setting

Key Highlights

  • remove

Guideline-Based Recommendations

Diagnosis

    Management

    • remove

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Patients aged over 18 with ECOG PS of 0-2

        Patients received at least two cycles of immunotherapy

        Clinical Best Practices

        • remove

        Related Resources & Content

        Original Source(s)

        Novel models for predicting individualized outcomes in patients with advanced hepatocellular carcinoma receiving immunotherapy

        • by Chao Chen, Yang Wang, Yan Zhao, Wenyan Cao, Ao Chen, Xiufeng Liu, Zhan Shi, Jie Shen

        • June 1, 2026

        Related Content

        Case Report: Tumor regression and neurological recovery in paraplegia from POLD1-mutated hepatocellular carcinoma treated with targeted immunotherapy and electroacupuncture

        Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and

        Lymph Node Dissection and Postoperative Complications After Lung Cancer Resection